drugset
drugset / Trial / NCT03414814

Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation

NCT03414814 ↗

Phase 2 Completed 15 enrolled Seoul National University Hospital AstraZeneca · collabKorean Cancer Study Group · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, non-randomized multicentre phase 2 study in NSCLC patients with EGFR exon 20 insertion mutation, whose disease has progressed on standard chemotherapy.

Timeline

Start
2018-01-04
Primary completion
2021-08-03
Completion
2021-08-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Osimertinib Small molecule 80 mg Oral

Indications

No indication recorded.